Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
12 July 2019 - 6:32AM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that it plans to issue a
press release before market open on Thursday, August 1,
2019 outlining its second quarter 2019 financial results.
In addition, the Company has scheduled a conference call
at 9:00 a.m. ET on the same day to discuss its second
quarter 2019 financial results. Hosting the call will be Douglas
Boothe, President and Chief Executive Officer and Duane Portwood,
Chief Financial Officer.
To access the call, please dial (844) 249-9382 in the U.S. and
+1 (270) 823-1530 for international callers. The conference ID is
7567263 . To access the live webcast, please go to Akorn’s Investor
Relations web site at http://investors.akorn.com.
A webcast replay of the conference call will be available
shortly following the conclusion of the call and will be available
for 90 days. To access the webcast replay, please go to Akorn’s
Investor Relations web site at http://investors.akorn.com.
About AkornAkorn, Inc. is a specialty
generic pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website
at www.akorn.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes statements that may
constitute "forward-looking statements", including expectations and
other statements regarding Akorn's goals and plans. When used in
this document, the words “will,” “expect,” “continue," “scheduled,”
“plans,” “intend,” and similar expressions are generally intended
to identify forward-looking statements. These statements are made
pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. A number of important
factors could cause actual results of Akorn and its subsidiaries to
differ materially from those indicated by such forward-looking
statements. Such risk factors include, but are not limited to: (i)
the effect of the Delaware court’s recent decision against Akorn on
Akorn’s ability to retain and hire key personnel, its ability to
maintain relationships with its customers, suppliers and others
with whom it does business, or its operating results and business
generally, (ii) the risk that ongoing or future litigation related
to the court’s decision may result in significant costs of defense,
indemnification and/or liability, (iii) the outcome of the
investigation conducted by Akorn with the assistance of outside
consultants, into alleged breaches of FDA data integrity
requirements relating to product development at Akorn and any
actions taken by Akorn, third parties or the FDA as a result of
such investigations, (iv) the difficulty of predicting the timing
or outcome of product development efforts, including FDA and other
regulatory agency approvals and actions, if any, (v) the timing and
success of product launches, (vi) difficulties or delays in
manufacturing, (vii) Akorn’s increased indebtedness and compliance
with certain covenants and other obligations under the Standstill
Agreement, which create material uncertainties and risks to its
growth and business outlook, (viii) Akorn’s obligation under the
Standstill Agreement to enter into a Comprehensive Amendment that
is satisfactory in form and substance to the Lenders, (ix) Akorn’s
obligation under the Standstill Agreement to pay certain fees and
expenses and increased interest margin, and (x) such other risks
and uncertainties outlined in the risk factors detailed in the
“Risk Factors” section of Akorn’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2018 (as filed with the
Securities and Exchange Commission (“SEC”) on March 1, 2019),
Akorn’s Quarterly Report on Form 10-Q for the fiscal quarter ended
March 31, 2019 (filed with the SEC on May 7, 2019) and other risk
factors identified from time to time in our filings with the SEC.
Readers should carefully review these risk factors, and should not
place undue reliance on the forward-looking statements. These
forward-looking statements are based on information, plans and
estimates at the date of this press release. Akorn undertakes no
obligation to update any forward-looking statements to reflect
changes in underlying assumptions or factors, new information,
future events or other changes.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2024 to May 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From May 2023 to May 2024